@article{46b55afecaf840d18cf0888e7ab95233,
title = "The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome",
abstract = "The revised Japanese clinical guidelines for myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome (LEMS) were published in 2022. The notable points in these guidelines (GLs) are as follows: (i) these are the first Japanese GLs to include a description of LEMS; (ii) diagnostic criteria of MG are revised to lessen the incidence of false negative patients; (iii) MG is divided into six clinical subtypes; (iv) a high-dose oral steroid regimen with escalation and de-escalation schedule is not recommended by the GLs; (v) the GLs promote the early fast-acting treatment strategy initially proposed in the previous GLs; (vi) refractory MG is defined; (vii) the use of molecular targeted drugs is included; (viii) diagnostic criteria of LEMS are proposed; and (ix) treatment algorithms for both MG and LEMS are presented. These new GLs are expected to improve the patients' quality of life and will serve to bridge the present era with the molecular targeted treatment eras.",
keywords = "Lambert–Eaton myasthenic syndrome, guidelines, molecular targeted treatment, myasthenia gravis, refractory, steroids",
author = "Hiroyuki Murai and Kimiaki Utsugisawa and Masakatsu Motomura and Tomihiro Imai and Akiyuki Uzawa and Shigeaki Suzuki",
note = "Funding Information: This review includes a study supported (in part) by a Health and Labor Sciences Research Grant on Rare and Intractable Diseases (Validation of Evidence‐based Diagnosis and Guidelines, and Impact on Quality of Life in Patients with Neuroimmunological Diseases) from the Ministry of Health, Labor and Welfare of Japan (Grant number: 20FC1030), and by JSPS KAKENHI (Grant number: 17K09780). We thank Mike Herbert, PhD, from Edanz Group ( https://en-author-services.edanz.com/ac ) for editing a draft of this manuscript. Funding Information: JSPS KAKENHI, Grant/Award Number: 17K09780; Ministry of Health, Labor and Welfare, Grant/Award Number: 20FC1030 Funding information Publisher Copyright: {\textcopyright} 2023 The Authors. Clinical and Experimental Neuroimmunology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society for Neuroimmunology.",
year = "2023",
month = feb,
doi = "10.1111/cen3.12739",
language = "English",
volume = "14",
pages = "19--27",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "1",
}